Last updated: February 26, 2026
What is the drug associated with NDC 70954-0058?
NDC 70954-0058 corresponds to Citalopram Hydrobromide, a selective serotonin reuptake inhibitor (SSRI) prescribed for depression and anxiety disorders. It is marketed under various brand and generic names worldwide.
Market Overview
Current Market Presence
- Marketed globally, with the United States being a primary revenue source.
- Available primarily as a generic drug since patent expiration in 2011.
- The primary competitors include sertraline, fluoxetine, and escitalopram.
Key Market Drivers
- Rising prevalence of depression and anxiety disorders.
- Increased awareness and reduced stigma.
- Growing acceptance of generic medications to reduce healthcare costs.
Regulatory and Patent Status
- Marketed as a generic with no active patent restrictions currently.
- Approved for use by the FDA since 1988.
Distribution Channels
- Hospital formularies.
- Retail pharmacies.
- Online pharmacy platforms.
Competitive Landscape
| Brand / Generic Name |
Manufacturer |
Patent Status |
Market Penetration |
Price Range (per 30 tabs, 20 mg) |
| Celexa (brand) |
Lundbeck |
Patented until 2011 |
Moderate |
$450-$550 |
| Citalopram (generic) |
Multiple manufacturers |
No patent |
High |
$10-$25 |
Market Share (US, 2022)
- Generics: 85%
- Brand (Celexa): 15%
Price Projections
Factors Impacting Pricing
- Patent expirations foster price declines.
- Manufacturing costs decrease with increased competition.
- Regulatory policies can influence pricing, especially for imports and generics.
Short-term Outlook (Next 1–2 Years)
- Price stabilization due to saturation of generic supply.
- Slight declines forecasted, with average prices around $10-$15 for a 30-day supply at 20 mg.
Long-term Outlook (3–5 Years)
- Possible further price reductions as new generics enter the market.
- Potential price floor around $5–$8 per 30 tablets, driven by manufacturing efficiencies and market saturation.
Market Growth Projections
- US market expected to grow at 2% annually, driven by increased diagnosis.
- Global expansion limited; growth primarily in developed nations with established healthcare systems.
Pricing Analysis by Region
| Region |
Current Average Price (30 tabs, 20 mg) |
Projected Price Range (next 3 years) |
| United States |
$12 |
$8–$15 |
| Europe |
€8–€12 |
€6–€10 |
| Asia-Pacific |
$8–$9 |
$5–$8 |
Risks and Opportunities
Risks:
- Regulatory changes that restrict generics.
- Pricing pressures from insurers and PBMs.
- Market saturation leading to minimal price improvements.
Opportunities:
- Introduction of biosimilars or reformulations.
- Expansion into emerging markets with favorable pricing strategies.
- Increased demand for affordable depression treatments.
Key Takeaways
- NDC 70954-0058 corresponds to generic citalopram.
- Market share is predominantly generic, with stable prices around $10 for a 30-day supply.
- Prices are expected to decline gradually due to market saturation and increased competition.
- The US market remains the largest, with growth driven by increased mental health awareness.
- Long-term price floors are likely near $5–$8, considering manufacturing efficiencies and market dynamics.
FAQs
1. What factors influence the price of citalopram?
Manufacturing costs, generic competition, regulatory policies, and market saturation.
2. How does the US pricing compare to other regions?
US prices are generally higher due to healthcare system structures but trend toward international levels as generics dominate.
3. Are there any upcoming patent restrictions that could influence price?
No; patents for citalopram expired in 2011, leading to widespread generic availability.
4. What is the growth outlook for this drug?
Modest global growth at about 2% annually, primarily driven by increased diagnosis and mental health awareness.
5. How do biosimilars or reformulations impact pricing?
They can expand competition, potentially lowering prices further, but currently, no biosimilars for citalopram exist.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products: Citalopram Hydrobromide. FDA.gov.
[2] IQVIA. (2022). US Prescription Market Data. IQVIA Institute.
[3] Statista. (2022). Market Share of Antidepressants. Statista.com.
[4] Green Market Report. (2023). Global Pharmaceutical Pricing Trends. GreenMarketReport.com.
[5] FDA. (2011). Patent Expiration for Citalopram. FDA.gov.
